The historical rank and industry rank for Oncopeptides AB's Pretax Margin % or its related term are showing as below:
FRA:OND'
s Pretax Margin % Range Over the Past 10 Years
Min: -4041.65 Med: -898.03 Max: -263.48
Current: -263.48
FRA:OND's Pretax Margin % is ranked worse than 62.86% of 945
companies
in the Biotechnology industry
Industry Median: -90.63
vs FRA:OND: -263.48
Oncopeptides AB (FRA:OND) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Oncopeptides AB Pretax Margin % Related Terms
Oncopeptides AB Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Oncopeptides AB's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:OND vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Oncopeptides AB's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncopeptides AB Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncopeptides AB's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Oncopeptides AB's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncopeptides AB (FRA:OND) has a Pretax Margin % of -126.30% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Oncopeptides AB and its competitors. According to the industry distribution chart, Oncopeptides AB ranks #594 out of 945 companies in the Biotechnology industry, placing it in the top 62.9%.
Is Oncopeptides AB's Pretax Margin % too high?
Oncopeptides AB's current Pretax Margin % is -126.30%. Based on the distribution chart, Oncopeptides AB ranks #594 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Oncopeptides AB has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncopeptides AB ranks #594 out of 945 companies for Pretax Margin %. This places Oncopeptides AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Oncopeptides AB and its competitors. Oncopeptides AB's current Pretax Margin % is -126.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (FRA:OND) is currently considered Possible Value Trap. The stock's GF Value™ is €0.36, compared to a current price of €0.14 — trading 60.5% below its estimated fair value. The current Pretax Margin % is -126.30%. Oncopeptides AB's overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Oncopeptides AB (FRA:OND), the current Pretax Margin % is -126.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncopeptides AB (FRA:OND) Overvalued in 2026?
Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued.
The current stock price of €0.14 is trading 60.5% below its estimated GF Value™ of €0.36.
GuruFocus considers Oncopeptides AB to be Possible Value Trap.
Key valuation signals for FRA:OND:
Pretax Margin %: -126.30%
GF Value™: €0.36 vs. price of €0.14 (60.5% below fair value)
No single metric tells the full story. See the FRA:OND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
36GF Score
Get the complete analysis for FRA:OND
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OND has been successfully added to your 
